PRESS-RELEASE ·Filed Nov 5, 2026
Press release · Earnings
Actionable Insight • Neutral
Monitor upcoming ACR Convergence 2026 presentations for one-year DM durability data and updated safety from the RESET program. The registrational myositis cohort enrollment trajectory and PC-free dose optimization data in 1H27 are key catalysts for the stock.
Price Chart
Loading chart...
Executive Summary
The company highlighted initiation of the RESET-SSc registrational cohort, planned BLA submission for rese-cel in myositis in 1Q28, and a cash runway into 1Q28 with $299.4M.
Key Facts
- Cash and equivalents $299.4M as of Sep 30, 2026, including $115M from warrant exercises
- R&D expenses $47.1M in Q3 2026 vs $39.8M in Q3 2025
- RESET-Myositis registrational topline results expected 2H27, BLA submission planned 1Q28
- RESET-SSc registrational cohort initiated in systemic sclerosis with interstitial lung disease
- PC-free program dose optimization data expected to inform 1H27 go-forward plans
- Cash runway extended into 1Q28
Financial Impact
Net loss $53.1M in Q3 2026, cash burn rate ~$18M/month based on $299.4M cash and 1Q28 runway
net losscash positionR&D expenses
Risk Factors
- Pre-revenue company with no approved products; depends on successful clinical development and regulatory approval
- Enrollment delays in registrational trials could push BLA timeline beyond 1Q28
- Safety events observed by other CAR T developers in autoimmune indications could impact patient/physician confidence
- Cash runway only into 1Q28; additional financing likely needed before potential commercialization
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396297 |
24 reports for CABA
57% Hit rate @ T+5 Went positive at some point 5 of 7 best @ T+60▲ +31.59%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 8, 2026 today | Press Release | No price | awaiting T+5 | awaiting T+5 | No price |
Nov 6, 2026 2d ago | SC 13G/A | $1.30 | awaiting T+5 | awaiting T+5 | $1.30 (+0.39%) |
Nov 6, 2026 2d ago | SC 13G/A | $1.31 | awaiting T+5 | awaiting T+5 | $1.30 (−0.38%) |
Nov 5, 2026 3d ago | 8-K | $1.28 | awaiting T+5 | awaiting T+5 | $1.30 (+1.56%) |
Nov 5, 2026 3d ago | Press Release | No price | awaiting T+5 | awaiting T+5 | No price |
Oct 30, 2026 9d ago | SC 13G/A | $1.51 $1.30 | ▼ −13.91% | ▼ −11.20% | $1.30 (−13.91%) |
Oct 27, 2026 11d ago | SC 13G/A | $1.52 $1.42 | ▼ −6.58% | ▼ −5.87% | $1.30 (−14.47%) |
Sep 14, 2026 7w ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.30 (−55.33%) |
Aug 15, 2026 12w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.30 (−55.02%) |
Aug 13, 2026 12w ago | 8-K | No price | awaiting T+5 | awaiting T+5 | No price |
Showing 10 of 24
US Market Status
Market Closed · Opens Mon (19h 40m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers